Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.

Watson-Jones, Deborah; Kavunga-Membo, Hugo; Grais, Rebecca F; Ahuka, Steve; Roberts, Natalie; Edmunds, W John; Choi, Edward M; Roberts, Chrissy H; Edwards, Tansy; Camacho, Anton; +9 more... Lees, Shelley; Leyssen, Maarten; Spiessens, Bart; Luhn, Kerstin; Douoguih, Macaya; Hatchett, Richard; Bausch, Daniel G; Muyembe, Jean-Jacques; DRC-EB-001 protocol writing team; (2022) Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo. BMJ open, 12 (3). e055596-. ISSN 2044-6055 DOI: https://doi.org/10.1136/bmjopen-2021-055596

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1136/bmjopen-2021-055596

Abstract

Share

Download

Filename: e055596.full.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar